醫學系婦產學科

Keyphrases

1. Taiwan 100%
2. Endometriosis 83%
3. Induced Pluripotent Stem Cells (iPSCs) 79%
4. Confidence Interval 64%
5. Taiwanese 64%
6. Adenomyosis 61%
7. Epithelial Ovarian Cancer 58%
8. Estrogen 55%
9. Retrospective Cohort Study 47%
10. Endometrial Cancer 42%
11. Myomectomy 41%
12. Postmenopausal Women 40%
13. Ovarian Cancer 40%
14. Uterine Sarcoma 39%
15. Laparoscopic Surgery 39%
16. Overall Survival 37%
17. Gonadotropin-releasing Hormone 36%
18. Cervical Cancer 36%
19. Laparoscopic Myomectomy 35%
20. Ovarian Cancer Patients 32%
21. Gestational Age 32%
22. Cisplatin 31%
23. Angiogenesis 31%
24. Operative Time 30%
25. Fallopian Tube Carcinoma 29%
26. Bipolar Coagulation 29%
27. Uterine Vessels 29%
28. Taiwanese Women 29%
29. Single Port 29%
30. Rare Case Report 29%
31. Endometrial Carcinoma 29%
32. Laparoscopic Cystectomy 29%
33. Overexpression 29%
34. Cyclooxygenase-2 28%
35. Obstetrics 27%
36. Advanced Stage 26%
37. Randomized Controlled Trial 26%
38. Prognostic Factors 26%
39. Ovarian Clear Cell Carcinoma 24%
40. Mouse Model 23%
41. Normal Pregnancy 23%
42. Agonist Treatment 23%
43. Hazard Ratio 23%
44. Transplantation 23%
45. Levonorgestrel-releasing Intrauterine System (LNG-IUS) 23%
46. Laparoscopy 22%
47. Single-port Laparoscopic 22%
48. Older Women 21%
49. Conventional Laparoscopic 21%
50. Stress Urinary Incontinence 21%
51. Myoma 21%
52. Cyclooxygenase-2 Expression 21%
53. C-Myc 20%
54. Hepatoprotective 20%
55. Liver Injury 19%
56. Symptomatic Uterine Fibroids 19%
57. Gynecologic Oncology Group 19%
58. Cervical Squamous Cell Carcinoma 19%
59. Invasive Cervical Cancer 19%
60. Power Doppler Ultrasound 19%
61. Ultraminilaparotomy 19%
62. ST6GAL1 19%
63. Parasitic Myoma 19%
64. Laparoscopic Morcellation 19%
65. PRISMA 19%
66. Ovarian Dermoid Cyst 19%
67. Endometrial Epithelial Cells 19%
68. Young Women 19%
69. Fallopian Tube 19%
70. Endometrioma Recurrence 19%
71. Cisplatin-based Chemotherapy 19%
72. Laparotomy 19%
73. Sialyltransferase 19%
74. Upper Abdominal Pain 19%
75. Gynecological Laparoscopic Surgery 19%
76. Estrogen Receptor 19%
77. Transobturator 19%
78. Laparoscopic Ovarian Drilling 19%
79. Wound Healing 19%
80. Mini 19%
81. Polycystic Ovary Syndrome 19%
82. Intervention Group 19%
83. Abdominal Pain 19%
84. Adverse Events 19%
85. Disease-free Survival 19%
86. Paclitaxel 18%
87. Recurrence Rate 18%
88. Fibroids 18%
89. Risk Factors 18%
90. Ifosfamide 17%
91. Cervical Tissue 17%
92. Endometrial Stromal Sarcoma 17%
93. Clear Cell Type 17%
94. Carbohydrate Antigen 125 (CA125) 17%
95. Incidence Rate 16%
96. Immunohistochemistry 16%
97. Dysmenorrhea 16%
98. Odds Ratio 16%
99. Dienogest 16%
100. Visual Analog Scale 16%

Medicine and Dentistry

1. Endometriosis 86%
2. Krukenberg Tumor 74%
3. Systematic Review 70%
4. Uterine Myomectomy 67%
5. Myoma 66%
6. Adenomyosis 63%
7. Ovarian Cancer 60%
8. Neoplasm 58%
9. Cervical Cancer 54%
10. Recurrent Disease 54%
11. Retrospective Cohort Study 47%
12. Uterine Cancer 45%
13. Cisplatin 44%
14. Diseases 43%
15. Gestational Age 43%
16. Overall Survival 42%
17. Pelvis 41%
18. Cystectomy 41%
19. Laparoscopic Surgery 41%
20. Pregnancy 40%
21. Uterus Sarcoma 39%
22. Induced Pluripotent Stem Cell 39%
23. Operation Duration 35%
24. Clear Cell Carcinoma 34%
25. Cyclooxygenase 2 33%
26. Cancer 33%
27. Uterine Fibroid 32%
28. Angiogenesis 31%
29. Bleeding 30%
30. Uterine Tube Carcinoma 29%
31. Morcellation 29%
32. Stress Incontinence 29%
33. Endometrium Carcinoma 29%
34. Adenocarcinoma 29%
35. Menorrhagia 29%
36. Obstetrics 28%
37. Gynecology 28%
38. Dentigerous Cyst 26%
39. First Trimester Pregnancy 26%
40. Prognostic Factor 25%
41. Randomized Controlled Trial 24%
42. Surgery 23%
43. Gonadorelin Agonist 23%
44. Disease Free Survival 22%
45. Metastatic Carcinoma 22%
46. Endometrium 22%
47. Squamous Cell Carcinoma 22%
48. Breast Cancer 21%
49. Mesenchymal-Epithelial Transition 21%
50. Doppler Flowmetry 21%
51. Doppler Ultrasound 21%
52. Carcinoma 21%
53. Ovarian Tumor 21%
54. Blood Flow 21%
55. Echography 20%
56. Immunohistochemistry 20%
57. Carcinosarcoma 19%
58. Gynecological Oncology 19%
59. Epithelial Cell 19%
60. Oncogene C Myc 19%
61. Therapy Effect 19%
62. Liver Injury 19%
63. Laparotomy 19%
64. Polycystic Ovary Syndrome 19%
65. Protein P53 19%
66. Hepatocyte 19%
67. Cytoreductive Surgery 18%
68. Postmenopause 18%
69. Adverse Event 18%
70. Paclitaxel 17%
71. Ifosfamide 17%
72. Proportional Hazards Model 16%
73. Carcinogenesis 16%
74. Dienogest 16%
75. Odds Ratio 16%
76. Cohort Analysis 16%
77. Hazard Ratio 16%
78. Cervix 15%
79. Carbon Dioxide 15%
80. Hysterectomy 15%
81. Recurrence Risk 15%
82. Dysmenorrhea 15%
83. Programmed Cell Death 15%
84. Cesarean Section 14%
85. Assisted Reproductive Technology 14%
86. Connective Tissue Cancer 14%
87. Premenopause 14%
88. Lymphadenopathy 14%
89. Lymph Node 14%
90. Lymph Node Metastasis 14%
91. Salpingooophorectomy 14%
92. Diagnosis 14%
93. Visual Analog Scale 14%
94. Premature Labor 14%
95. Postoperative Pain 14%
96. Maintenance Therapy 13%
97. Observational Study 13%
98. Vaginal Hysterectomy 13%
99. Progression Free Survival 13%
100. Case-Control Study 13%